OBJECTIVE：To observe the efficacy and safety of azithromycin sequential therapy combined with terbutaline in the treatment of mycoplasma pneumonia. METHODS： 130 children with mycoplasma pneumonia were randomly divided into control group and observation group. Control group was given azithromycin sequential therapy by using 10 mg/kg Azithromycin dispersible tablet by intravenous infusion， once a day， for continuous 3-5 d， then rested for 4 d，and then given 10 mg/kg Azithromycin dispersible tablet at a draught， once a day， for continuous 3 d， then rested for 4 d； observation group was additionally given 2.5 mg Terbutaline injection adding into 5 ml sodium chloride injection by inhalation via oxygen atomization， twice a day， 10-15 min every times， and then the children were fed with warm boiled waterafter atomization. The treatment course for both groups was 4 weeks. Clinical efficacy， and changes of cytokines levels [tumor necrosis factor-α （TNF-α）， interleukin-6 （IL-6）， IL-8]， disappeared time of related symptoms and signs （wheezing， rales， coughing， fever）， hospitalization time before and after treatment， and incidence of adverse reactions in 2 groups were observed. RESULTS：After treatment，the effective rate in observation group was significantly higher than control group， levels of TNF-α， IL-6 and IL-8 were significantly lower than control group， disappeared time of related symptoms and signs and hospitalization time were significantly shorter than control group， the differences were statistically significant（P＜0.05）. There was no significant difference in the incidence of adverse reactions between 2 groups（P＞0.05）. CONCLUSIONS： Azithromycin sequential therapy combined with terbutalineaerosol therapycan effectively improve the cytokines levels and clinical efficacy， with good safety.